FrancophonIA/ELRC3.0 huggingface dataset:
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one fifth (1/5) of the dose volume of Dexdomitor 0.1 mg/ml that was given to the dog, regardless of route of administration of Dexdomitor.
Croatian: Volumen doze atipamezola pri koncentraciji od 5 mg/ml iznosi jednu petinu (1/5) volumena doze Dexdomitora 0,1 mg/ml koji je primijenjen na psu, neovisno o putu primjene Dexdomitora.
English: The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of Dexdomitor that was given to the dog, regardless of route of administration of Dexdomitor.
Croatian: Volumen doze atipamezola pri koncentraciji od 5 mg/ml jednak je volumenu doze Dexdomitora primijenjenom na psu, neovisno o putu primjene Dexdomitora.
English: The dose volume of atipamezole at the concentration of 5 mg/ml equals one-half the volume of Dexdomitor that was given to the cat.
Croatian: Volumen doze atipamezola pri koncentraciji od 5 mg/ml jednak je polovini volumena Dexdomitora primijenjenom na mački.
English: Methyl parahydroxybenzoate (E 218) 2.0 mg/ml Propyl parahydroxybenzoate (E 216) 0.2 mg/ml
Croatian: Metil parahidroksibenzoat (E 218) 2,0 mg/ml Propil parahidroksibenzoat (E 216) 0,2 mg/ml
English: Methyl parahydroxybenzoate (E 218) 1.6 mg/ml Propyl parahydroxybenzoate (E 216) 0.2 mg/ml
Croatian: Metil parahidroksibenzoat (E 218) 1,6 mg/ml Propil parahidroksibenzoat (E 216) 0,2 mg/ml
English: MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/003
Croatian: 16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/02/033/003
English: METHOD AND ROUTE(S) OF ADMINISTRATION Dogs: intravenous or intramuscular use Cats: intramuscular use
Croatian: METODE I NAČIN PRIMJENE Psi: intravenska ili intramuskularna primjena Mačke: intramuskularna primjena Prije upotrebe pročitati uputu o VMP.
English: DOGS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Croatian: PSI: U slučajevima predoziranja ili ako učinci deksmedetomidina postanu potencijalno životno ugrožavajući, prikladna doza atipamezola je 10 puta veća od inicijalne doze deksmedetomidina (mikrogrami/kg tjelesne težine ili mikrogrami/četvornom metru površine tijela).
English: Dogs: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Croatian: Psi: U slučajevima predoziranja ili ako učinci deksmedetomidina postanu potencijalno životno ugrožavajući, prikladna doza atipamezola je 10 puta veća od inicijalne doze deksmedetomidina (mikrogrami/kg tjelesne težine ili mikrogrami/četvornom metru površine tijela).
English: NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.5 mg/ml solution for injection
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA DEXDOMITOR 0,5 mg/ml otopina za injekciju
English: Cats: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.
Croatian: Mačke: U slučajevima predoziranja ili ako učinci deksmedetomidina postanu potencijalno životno ugrožavajući, prikladni antagonist je atipamezol, primijenjen intramuskularnom injekcijom u sljedećoj dozi: peterostruka inicijalna doza deksmedetomidina u mikrogramima/kg tjelesne težine.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.1 mg/ml solution for injection
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA DEXDOMITOR 0,1 mg/ml otopina za injekciju
English: PACKAGE LEAFLET DEXDOMITOR 0.5 mg/ml solution for injection
Croatian: UPUTA O VMP DEXDOMITOR 0,5 mg/ml otopina za injekciju
English: 3 years
Croatian: 6.3 Rok valjanosti
English: PACKAGE LEAFLET DEXDOMITOR 0.1 mg/ml solution for injection
Croatian: UPUTA O VMP DEXDOMITOR 0,1 mg/ml otopina za injekciju
English: Excipients:
Croatian: Serija:
English: The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume 0.08 ml Dexdomitor/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Croatian: Doza za mačke je 40 mikrograma deksmedetomidin hidroklorida/kg tjelesne mase, jednako volumenu doze 0,08 ml Dexdomitora/kg tjelesne mase pri korištenju za neinvazivne, blago do umjereno bolne zahvate koji zahtijevaju obuzdavanje, sedaciju i analgeziju.
English: The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/ kg bw equal to a dose volume 0.08 ml Dexdomitor/ kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Croatian: Doza za mačke je 40 mikrograma deksmedetomidin hidroklorida/kg tjelesne mase, jednako volumenu doze od 0,08 ml Dexdomitor/kg tjelesne mase pri korištenju za neinvazivne, blago do umjereno bolne zahvate koji zahtijevaju obuzdavanje, sedaciju i analgeziju.
English: The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume 0.4 ml Dexdomitor/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Croatian: Doza za mačke je 40 mikrograma deksmedetomidin hidroklorida/kg tjelesne mase, jednako volumenu doze od 0,4 ml Dexdomitora/kg tjelesne mase pri korištenju za neinvazivne, blago do umjereno bolne zahvate koji zahtijevaju obuzdavanje, sedaciju i analgeziju.
English: 15 ml
Croatian: 4. VELIČINA PAKOVANJA 15 ml
English: PHARMACEUTICAL FORM Solution for injection Clear, colourless solution
Croatian: Bistra, bezbojna otopina
English: VIAL/MULTI PACKAGE
Croatian: Vrsta i sastav unutarnjeg pakovanja
English: 0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine
Croatian: 2. NAVOĐENJE DJELATNIH I DRUGIH TVARI 1 ml sadrži 0,5 mg deksmedetomidin hidroklorida ekvivalentno 0,42 mg dexmedetomidina
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients Methyl parahydroxybenzoate (E 218) Propyl parahydroxybenzoate (E 216) 6.2 Incompatibilities
Croatian: Metil parahidroksibenzoat (E 218) Propil parahidroksibenzoat (E 216)
English: • Increased blood pressure
Croatian: • povišen krvni tlak
English: See section 4.
Croatian: Pogledajte dio 4..
English: What Evista is and what it is used for
Croatian: Što je Evista i za što se koristi
English: Your doctor will tell you how long you should continue to take Evista.
Croatian: Vaš liječnik će Vam reći koliko dugo trebate uzimati Evistu.
English: If you take more Evista than you should
Croatian: Ako uzmete više Eviste nego što ste trebali
English: Evista may affect the development of the baby.
Croatian: Evista može utjecati na razvoj djeteta.
English: Date of latest renewal: 8 August 2008
Croatian: Datum posljednje obnove odobrenja: 8. kolovoza 2008.
English: Do not take Evista:
Croatian: Nemojte uzimati Evistu:
English: D-81379 Munich Germany
Croatian: D-81379 München Njemačka
English: Evista could harm your unborn child.
Croatian: Evista može naškoditi Vašem nerođenom djetetu.
English: No dose adjustment is necessary for the elderly.
Croatian: Prilagođavanje doze kod starijih nije potrebno.
English: Other medicines and Evista
Croatian: Drugi lijekovi i Evista
English: • If there is still a possibility that you can get pregnant, Evista could harm your unborn child.
Croatian: • Ako još postoji mogućnost da zatrudnite, Evista može naškoditi Vašem nerođenom djetetu.
English: If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, your doctor may need to adjust your dose of these medicines.
Croatian: Ako zbog srca uzimate lijekove koji sadrže digitalis ili antikoagulanse poput varfarina za razrjeđivanje Vaše krvi, liječnik će Vam možda trebati prilagoditi doze tih lijekova.
English: It is important that you continue taking Evista for as long as your doctor prescribes the medicine.
Croatian: Važno je da nastavite uzimati Evistu onoliko dugo koliko je liječnik propisao lijek.
English: Evista can treat or prevent your osteoporosis only if you continue to take the tablets.
Croatian: Evista može liječiti Vašu osteoporozu ili ju spriječiti samo ako nastavite uzimati tablete.
English: Common: Peripheral oedema
Croatian: Često: periferni edemi
English: Forty five women with osteoporosis or 15 women with osteoporosis with an existing fracture would need to be treated with Evista for 3 years to prevent one or more vertebral fractures.
Croatian: Četrdeset i pet žena s osteoporozom ili 15 žena s osteoporozom s postojećim prijelomom morale bi se liječiti Evistom tijekom 3 godine da bi se spriječio nastanak jednog ili više prijeloma kralježaka.
English: Warnings and precautions Talk to your doctor or pharmacist before you take Evista.
Croatian: Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete Evistu.
English: What you need to know before you take Evista
Croatian: Što morate znati prije nego počnete uzimati Evistu
English: After 3 years therapy Evista decreased fibrinogen (6.71 %).
Croatian: Nakon 3-godišnje terapije Evista je smanjila fibrinogen (6,71 %).
English: Evista tablets are packed either in PVC/PE/PCTFE blisters or in high density polyethylene bottles.
Croatian: Evista tablete pakirane su ili u PVC/PE/PCTFE blistere ili u boce od polietilena visoke gustoće.
English: ii) Bone Mineral Density (BMD): The efficacy of Evista once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period.
Croatian: ii) Mineralna gustoća kosti (BMD): Djelotvornost Eviste primijenjene jednom dnevno u žena u postmenopauzi do 60 godina života s maternicom ili bez nje utvrđena je tijekom dvogodišnjeg liječenja.
English: A similar increase in BMD was seen in the treatment population who received Evista for up to 7 years.
Croatian: Slično povećanje BMD-a uočeno je i u liječenoj skupini koja je dobivala Evistu do 7 godina.
English: e) Effects on cognitive function
Croatian: e) Učinci na kognitivne funkcije
English: Evista is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Croatian: Evista se primjenjuje isključivo u žena u postmenopauzi i ne smiju je uzimati žene koje još uvijek mogu zatrudnjeti.
English: Evista does not stimulate breast tissue.
Croatian: Evista ne stimulira tkivo dojke.
English: • Headache including migraine
Croatian: • glavobolja uključujući migrenu
English: What Evista is and what it is used for What you need to know before you take Evista How to take Evista
Croatian: Što je Evista i za što se koristi Što morate znati prije nego počnete uzimati Evistu Kako uzimati Evistu
English: Clinical trials showed that a 60 mg daily dose of Evista significantly decreased total cholesterol (3 to 6 %), and LDL cholesterol (4 to 10 %).
Croatian: Klinička ispitivanja pokazala su da dnevna primjena Eviste u dozi od 60 mg značajno snižava razinu ukupnog kolesterola (3 do 6 %) i LDL-kolesterola (4 do 10 %).
English: Do not take Evista if you are breast-feeding as it might be excreted in mother's milk.
Croatian: Nemojte uzimati Evistu ako dojite budući da se lijek može izlučivati u majčino mlijeko.
English: Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, because Evista may not work as well.
Croatian: Recite svom liječniku ako uzimate kolestiramin, koji se uglavnom koristi kao lijek za snižavanje razine masnoća, jer Evista možda neće djelovati jednako dobro.
English: If you stop taking Evista
Croatian: Ako prestanete uzimati Evistu
English: Evista was associated with reduced bone resorption and a mean positive shift in calcium balance of 60 mg per day, due primarily to decreased urinary calcium losses.
Croatian: Evista je povezana sa smanjenjem resorpcije kosti i sa srednjim pozitivnim pomakom u ravnoteži kalcija od 60 mg dnevno prije svega zbog smanjenog gubitka kalcija urinom.
English: However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Evista.
Croatian: Međutim, ako ste u prošlosti uzimali estrogen i pri tome imali veliki porast razine triglicerida, posavjetujte se sa svojim liječnikom prije nego počnete uzimati Evistu.
English: There is no relevant use of Evista in the paediatric population.
Croatian: Nema relevantne primjene Eviste u pedijatrijskoj populaciji.
English: In rare cases, blood levels of liver enzymes may increase during treatment with Evista.
Croatian: U rijetkim slučajevima, razine jetrenih enzima u krvi mogu porasti za vrijeme liječenja Evistom.
English: Evista should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Croatian: Evistu ne smiju uzimati bolesnice sa znacima ili simptomima raka endometrija jer sigurnost u toj skupini bolesnica nije još dovoljno ispitana.
English: Evista belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs).
Croatian: Evista pripada skupini lijekova koji nisu hormoni, a koji se nazivaju selektivnim modulatorima estrogenskih receptora.
English: The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Croatian: Unutar svake grupe učestalost nuspojave klasificirana je na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko
English: Effects on prothrombin time may develop over several weeks if Evista treatment is started in patients who are already on coumarin anticoagulant therapy.
Croatian: Učinci na protrombinsko vrijeme mogu se razviti tijekom nekoliko tjedana nakon što se uvede terapija Evistom bolesnicama koje već uzimaju kumarinsku antikoagulantnu terapiju.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Croatian: Bolesnice s rijetkim nasljednim poremećajem nepodnošenja galaktoze, nedostatkom Lapp laktaze ili glukoza-galaktoza malapsorpcijom ne bi trebale uzimati ovaj lijek.
English: Evista mimics some of the helpful effects of oestrogen after the menopause.
Croatian: Evista oponaša neke korisne učinke estrogena nakon menopauze.
English: How Evista works
Croatian: Kako Evista djeluje
English: Endometrial biopsies taken after six months therapy with Evista 60 mg daily demonstrated nonproliferative endometrium in all patients.
Croatian: Biopsije endometrija uzete nakon šestomjesečne terapije Evistom u dozi od 60 mg dnevno u svih su bolesnica pokazale neproliferativni endometrij.
English: If you take more Evista than you should you could have leg cramps and dizziness.
Croatian: Ako uzmete više Eviste nego što ste trebali mogu se pojaviti grčevi u nogama i omaglica.
English: Blister boxes contain 14, 28, or 84 tablets.
Croatian: Blister pakiranja sadrže 14, 28 ili 84 tablete.
English: Any uterine bleeding during Evista therapy is unexpected and should be fully investigated by a specialist.
Croatian: Svako krvarenje iz maternice tijekom liječenja Evistom nije očekivano te ga specijalist mora u potpunosti ispitati.
English: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Croatian: Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1..
English: Evista (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials.
Croatian: Evista (n = 317) je uspoređena s kontinuiranom kombiniranom hormonskom nadomjesnom terapijom (HNT) (n = 110) ili cikličkom HNT-om (n = 205) u bolesnica tijekom nekih kliničkih ispitivanja.
English: Evista therapy for 8 years did not significantly affect the risk of cardiovascular events in patients enrolled in the osteoporosis treatment study.
Croatian: Liječenje Evistom u trajanju od 8 godina nije značajno utjecalo na rizik nastanka srčano-krvožilnih događaja u bolesnica uključenih u ispitivanje liječenja osteoporoze.
English: Therefore, Evista should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed.
Croatian: Stoga Evistu treba uzimati u liječenju i prevenciji osteoporoze samo nakon što je liječenje karcinoma dojke, uključujući i adjuvantnu terapiju, završeno.
English: Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines.
Croatian: Često istodobno primijenjivani lijekovi uključivali su: paracetamol, nesteroidne protuupalne lijekove (kao što su acetilsalicilna kiselina, ibuprofen i naproksen), oralne antibiotike, H1-antagoniste, H2-antagoniste i benzodiazepine.
English: Very common: Increased blood pressure a a Term(s) included based on postmarketing experience.
Croatian: Pretrage Vrlo često: povišen krvni tlaka a Uključeni pojmovi na temelju postmarketinškog iskustva.
English: Marketing Authorisation Holder Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, D-81379 Munich, Germany.
Croatian: Nositelj odobrenja za stavljanje lijeka u promet Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, D-81379 München, Njemačka.
English: If you forget to take Evista
Croatian: Ako ste zaboravili uzeti Evistu
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Croatian: POSEBNE MJERE ZA ZBRINJAVANJE NEISKORIŠTENOG LIJEKA ILI OTPAdNIH MATERIJALA KOJI POTJEČU
English: Very common: Vasodilation (hot flushes)
Croatian: Vrlo često: vazodilatacija (navale crvenila uz osjećaj vrućine)
English: Evista should be discontinued in the event of an illness or a condition leading to a prolonged period of immobilisation.
Croatian: Liječenje Evistom treba se prekinuti u slučaju nastanka bolesti ili stanja koja dovode do dugotrajne imobilizacije.
English: No data are available on the concomitant use of Evista and agents used in the treatment of early or advanced breast cancer.
Croatian: Nema raspoloživih podataka o istodobnom uzimanju Eviste i lijekova koji se koriste u liječenju ranog ili uznapredovalog karcinoma dojke.
English: The clinically most important adverse reactions reported in postmenopausal women treated with Evista were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients.
Croatian: Klinički najznačajnije nuspojave prijavljene kod žena u postmenopauzi liječenih Evistom bili su venski tromboembolijski događaji (vidjeti dio 4.4) koji su se pojavili u manje od 1% liječenih bolesnica.
English: Evista and oestrogen affect bone remodelling and calcium metabolism similarly.
Croatian: Evista i estrogen slično utječu na pregradnju kosti i metabolizam kalcija.
English: Raloxifene is associated with an increased risk for venous thromboembolic events that is similar to the reported risk associated with current use of hormone replacement therapy.
Croatian: Primjena raloksifena povezana je s povećanim rizikom od razvoja venskih tromboembolijskih događaja koji je sličan onom prijavljenom riziku pri primjeni hormonske nadomjesne terapije.
English: It is unlikely that Evista will cause vaginal bleeding.
Croatian: Nije vjerojatno da će Evista uzrokovati krvarenje iz rodnice.
English: If this medicinal product is used mistakenly during pregnancy or the patient becomes pregnant while taking it, the patient should be informed of the potential hazard to the foetus (see section 5.3).
Croatian: Ako se lijek greškom uzme tijekom trudnoće ili tijekom uzimanja lijeka bolesnica ostane trudna, bolesnicu se mora upozoriti o mogućim opasnostima za fetus (vidjeti dio
English: INFORMATION IN BRAILLE Evista
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Evista
English: In addition, in a study with 2.5 x the recommended daily dose of Evista there was no evidence of endometrial proliferation and no increase in uterine volume.
Croatian: Nadalje, u ispitivanju u kojemu je primijenjena doza raloksifena 2,5 puta veće od preporučene dnevne doze Eviste nije postojao dokaz o proliferaciji endometrija niti povećanje volumena maternice.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 5 August 1998
Croatian: Datum prvog odobrenja: 5. kolovoza 1998.
English: Concurrent administration of either calcium carbonate or aluminium and magnesium-hydroxide containing antacids do not affect the systemic exposure of raloxifene.
Croatian: Istodobna primjena antacida koji sadrže kalcijev karbonat ili aluminijev i magnezijev hidroksid ne utječe na sistemsku izloženost raloksifenu.
English: When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).
Croatian: Prilikom odluke o izboru Eviste ili drugih terapija, uključujući i estrogensku terapiju, u pojedinih žena u postmenopauzi moraju se uzeti u obzir simptomi menopauze, učinci na tkivo maternice i dojke te srčano-krvožilni rizici i koristi (vidjeti dio 5.1).
English: Driving and using machines Evista has no or negligible effects on driving or using machines.
Croatian: Upravljanje vozilima i strojevima Evista ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima ili strojevima.
English: In clinical trials, Evista did not stimulate the postmenopausal uterine endometrium.
Croatian: U kliničkim istraživanjima Evista nije stimulirala endometrij maternice u postmenopauzi.
English: Raloxifene decreases resorption of bone; this effect on bone is manifested as reductions in the serum and urine levels of bone turnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in BMD and decreases in the incidence of fractures.
Croatian: Raloksifen smanjuje resorpciju kosti; taj učinak na kosti iskazuje se smanjenjem razine biljega koštane pregradnje u serumu i urinu, smanjenjem resorpcije kosti na temelju ispitivanja kinetike radioaktivno-obilježenog kalcija, povećanjem BMD-a i smanjenjem incidencije prijeloma.
English: • If you have active uterine cancer, as there is insufficient experience of Evista use in women with this disease.
Croatian: • Ako imate aktivni karcinom maternice, s obzirom na to da ne postoji dovoljno iskustva s primjenom Eviste u žena s tom bolešću.
English: Evista is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with oestrogen deficiency.
Croatian: Evista nije učinkovita u smanjivanju vazodilatacije (navala crvenila uz osjećaj vrućine) niti drugih simptoma menopauze povezanih s manjkom estrogena.
English: Based on these risk factors, prevention of osteoporosis with Evista is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures.
Croatian: Na temelju navedenih rizičnih čimbenika prevencija osteoporoze Evistom indicirana je u žena unutar deset godina od nastupa menopauze, s vrijednošću BMD-a kralježnice u rasponu od 1,0 do 2,5 SD ispod srednje vrijednosti zdrave mlade populacije, uzimajući u obzir visoki doživotni rizik od nastanka osteoporotičnih prijeloma.
English: Raloxifene has no or negligible influence on the ability to drive and use machines.
Croatian: Raloksifen ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.